(264 days)
Not Found
Not Found
No
The document describes in vitro diagnostic reagents for measuring various analytes in serum using a specific analyzer. There is no mention of AI, ML, image processing, or any other technology typically associated with AI/ML applications in medical devices. The focus is on the chemical reagents and their intended use for diagnostic measurements.
No
The device is for in vitro diagnostic measurements of various substances in serum for the purpose of diagnosis and treatment of diseases, not for therapeutic intervention.
Yes
The "Intended Use / Indications for Use" section explicitly states that the measurements performed by this device, such as bilirubin, phosphorus, iron, and magnesium measurements, are "used in the diagnosis and treatment" of various diseases and disorders.
No
The device is described as a reagent for in vitro measurement on a specific analyzer, indicating it is a chemical substance used with a hardware device, not a standalone software product.
Yes, this device is an IVD (In Vitro Diagnostic).
The key phrase that indicates this is an IVD is "for the in vitro measurement" which appears multiple times in the "Intended Use / Indications for Use" section for each reagent.
In vitro diagnostics are tests performed on samples such as blood, urine, or tissue that have been taken from the human body to detect diseases or other conditions. The description clearly states that these reagents are used to measure substances (Direct Bilirubin, Total Bilirubin, Phosphorus, Iron, Magnesium) in serum specimens, which are samples taken from the body.
N/A
Intended Use / Indications for Use
The EasyRA DBIL Reagent is for the in vitro measurement of Direct Billirubin in serum specimens of adults on the Medica EasyRA analyzer. Bilirubin measurements are used in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and gall bladder block, The EasyRA TBIL Reagent is for the in vitro measurement of Total Bilirubin in serum specimens of adults on the Medica EasyRA analyzer. Bilirubin measurements are used in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and gall bladder block. The EasyRA Phosphorus Reagent is for the in vitro measurement of phosphorus in serum on the Medica EasyRA analyzer. Phosphorus measurements are used in the diagnosis and treatment of parathyroid gland, kidney diseases, and vitamin D imbalance. The EasyRA Iron Reagent is for the in vitro measurement of iron in serum on the Medica EasyRA analyzer. Iron measurements are used in the diagnosis and treatment of iron deficiency anemia, hemochromatosis, and chronic renal disease. The EasyRA Magnesium Reagent is for the in vitro measurement of phosphorus in serum on the Medica EasyRA analyzer. Magnesium measurements are used in the diagnosis and treatment of: Hypermagnesemia occurring during renal failure, acute diabetic acidosis, dehydration or in Addison's disease. Hypomagnesemia observed in cases of chronic alcoholism, malabsorption, acute pancreatitis and kidney disorders.
Product codes
CIG, CEO, JIY, JGJ
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adults
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1110 Bilirubin (total or direct) test system.
(a)
Identification. A bilirubin (total or direct) test system is a device intended to measure the levels of bilirubin (total or direct) in plasma or serum. Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal distruction of red blood cells, if used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder block.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the symbol of the Department of Health & Human Services on the left and the text "FDA U.S. FOOD & DRUG ADMINISTRATION" on the right. The text is in blue, with "FDA" in a larger font size than the rest of the text.
June 11, 2018
Medica Corp. Photios Makris Director, QA/RA 5 Oak Park Drive Bedford, MA 01730
Re: K080810
Trade/Device Name: EasyRA Bilirubin-Direct Reagent, EasyRA Bilirubin-Total Reagent, EasyRA Phosphorus-Inorganic Reagent, EasyRA Iron Reagent, EasyRA Magnesium Reagent Regulation Number: 21 CFR 862.1110 Regulation Name: Bilirubin (total or direct) test system Regulatory Class: Class II Product Code: CIG, CEO, JIY, JGJ Dated: December 5, 2008 Received: December 9, 2008
Dear Photios Makris:
This letter corrects our substantially equivalent letter of December 10, 2008.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indication for Use
510(k) Number (if known): K080810
Device Name: EasyRA Bilirubin-Direct Reagent Indication For Use: The EasyRA DBIL Reagent is for the in vitro measurement of Direct Billirubin in serum specimens of adults on the Medica EasyRA analyzer. Bilirubin measwements are used in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and gall bladder block, EasyRA Bilirubin-Total Reagent Device Name: The EasyRA TBIL Reagent is for the in vitro measurement of Total Bilirubin in Indications For Use: serum specimens of adults on the Medica EasyRA analyzer. Bilirubin measwements are used in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and gall bladder block. Device Name: EasyRA Phosphorus Reagent The EasyRA Phosphorus Reagent is for the in vitro measurement of phosphorus Indications For Use: in serum on the Medica EasyRA analyzer. Phosphorus measurements are used in the diagnosis and treatment of parathyroid gland, kidney diseases, and vitamin D imbalance. Device Name: EasyRA Iron Reagent Indications For Use: The EasyRA Iron Reagent is for the in vitro measurement of iron in serum on the Medica EasyRA analyzer. Iron measurements are used in the diagnosis and treatment of iron deficiency anemia, hemochromatosis, and chronic renal disease. Device Name: EasyRA Magnesium Reagent The EasyRA Magnesium Reagent is for the in vitro measurement of phosphorus Indications For Use: in serum on the Medica EasyRA analyzer. Magnesium measurements are used in the diagnosis and treatment of: Hypermagnesemia occuring during renal failure, acute diabetic acidosis, dehydration or in Addison's disease. Hypomagnesemia observed in cases of chronic alcoholism, malabsorption, acute pancreatitis and kidney disorders.
Prescription Use X (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Carol C. Benson
Division Sign-O Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K080810